Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
about
Long-term drug treatment of patients with alcohol dependenceAlcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinenceGlutamatergic targets for new alcohol medicationsTranscranial magnetic stimulation: potential treatment for co-occurring alcohol, traumatic brain injury and posttraumatic stress disordersThe development of acamprosate as a treatment against alcohol relapseA critical review of the literature on attentional bias in cocaine use disorder and suggestions for future researchAcamprosate: A Review of Its Use in Alcohol DependenceA general method for handling missing binary outcome data in randomized controlled trialsA Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizationsBarriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependenceIntention-to-treat analyses and missing data approaches in pharmacotherapy trials for alcohol use disordersNalmefene for the treatment of alcohol use disorders: recent data and clinical potential.First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.A meta-analysis of topiramate's effects for individuals with alcohol use disorders.The Genetics, Neurogenetics and Pharmacogenetics of AddictionAlcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.Pharmacotherapy for alcoholic patients with alcoholic liver diseaseAlcohol use disorder: pathophysiology, effects, and pharmacologic options for treatmentThe efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.An open-label pilot study of icariin for co-morbid bipolar and alcohol use disorder.Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studiesThe management of alcohol use disorders: the impact of pharmacologic, affective, behavioral, and cognitive approaches.Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate.Views about responsibility for alcohol addiction and negative evaluations of naltrexone.Fetal alcohol spectrum disorders and neuroimmune changesSocial network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing?Access to Addiction Pharmacotherapy in Private Health Plans.Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision.Correlates of Baclofen Effectiveness in Alcohol DependenceCritical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal StudySafety and efficacy of acamprosate for the treatment of alcohol dependence.Pharmacotherapy for alcohol use disorder: current and emerging therapiesPreclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation.The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta-analysis.Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial.
P2860
Q26773332-08BFBCB6-2AF3-4AFB-8F03-C654922091FDQ26801196-3F153869-3E79-42EF-93EF-0A15D20208EEQ26824012-0A3BAC5C-4C23-4BAD-82AD-40E5A6302A8FQ26825659-4965D532-04E6-44BA-B02E-C62BB429C545Q26862199-999F8CE9-7687-411C-A91E-B6877957EB7DQ27012850-0B2D9BCD-C888-4F17-BBCC-92167BD52269Q28263633-4C620415-1783-4D13-B878-C76E1E39640BQ28651585-EF9AACCA-042B-427A-870E-7830AE953281Q30275691-E85E99B7-CBAF-42B9-8EF6-1AB80C2DC135Q30373948-229B7F08-BEF2-44A4-8533-5ACE938AA97CQ30401713-7D148AAD-6119-4882-9576-674831A9DDFCQ30412161-D8246F5A-0993-46F5-839D-F5D2FA66DC6FQ30694681-4E511438-06E4-405F-934F-914FB7C0DDF6Q31039835-DCF3A3FC-5429-4EDD-82C9-99874822D63FQ33675540-EE76D880-877A-4D8B-80C2-6AF069641F74Q33717597-02E0EB28-5B5C-4229-AD4E-3F607AB65F35Q33898930-41E262A4-30A5-458D-8245-6DF10F202D69Q34018001-FEA0885C-F0A3-44B1-989E-3DD7C5506805Q34223054-A5A7D31C-16C3-4EE8-AD41-AD97E90871E7Q34411076-8191238C-4F35-422E-BC91-CD4ED333C0F7Q34461886-82590DF9-2287-474D-AB0E-F91720DB4F0FQ34510739-62A35717-FB9B-4011-893E-03C604ABBE72Q34654500-8D07980A-E3ED-43E7-BFE8-19BFB4BDE5C1Q35054237-61210950-FE6D-4066-A363-0AE91788AB59Q35150158-FA62CC2E-77B8-4DBC-BB13-F71ED80C9C50Q35204253-829660F8-318E-4DFA-A5FD-A413E3409C43Q35294500-004DC84E-A21B-4F82-B3E2-F6E858FB7306Q35565599-5109FFFB-94F4-4C29-897C-BABE228F160BQ35822064-95BADCD3-2E1C-4D12-BAC6-84546DEE7382Q36025907-118B6401-23EC-4E24-A957-2922977F4E16Q36043383-F201862B-14CF-442A-B32C-91FACD2E3896Q36231851-15A399DF-EC79-41D0-8ADC-E37829F0964FQ36291897-568940DE-A1EE-4E3D-854E-79132AD4ABB8Q36372867-E975330E-D1DF-4B0B-B27A-2D919D46A4CFQ36494890-1451F351-0845-4014-9094-964461F8F0A0Q36590706-026C6F7D-B902-4E60-9F5C-C8BD4E99282AQ36684437-3E412F78-D895-4B4C-AEA5-2915EC2BA862Q36852840-C1DCFE60-D939-4334-A8C9-6C0ADFEDBA04Q36854209-6492BBBB-8A1E-43A4-BBF5-68527BA6959FQ37059531-2120CB44-DCAC-44D3-8585-410520807DF0
P2860
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Meta-analysis of naltrexone an ...... hese medications most helpful?
@ast
Meta-analysis of naltrexone an ...... hese medications most helpful?
@en
Meta-analysis of naltrexone an ...... hese medications most helpful?
@nl
type
label
Meta-analysis of naltrexone an ...... hese medications most helpful?
@ast
Meta-analysis of naltrexone an ...... hese medications most helpful?
@en
Meta-analysis of naltrexone an ...... hese medications most helpful?
@nl
prefLabel
Meta-analysis of naltrexone an ...... hese medications most helpful?
@ast
Meta-analysis of naltrexone an ...... hese medications most helpful?
@en
Meta-analysis of naltrexone an ...... hese medications most helpful?
@nl
P2093
P2860
P921
P1433
P1476
Meta-analysis of naltrexone an ...... hese medications most helpful?
@en
P2093
Janet C Blodgett
John W Finney
Natalya C Maisel
Paula L Wilbourne
P2860
P304
P356
10.1111/J.1360-0443.2012.04054.X
P407
P577
2012-10-17T00:00:00Z